Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
or

Bright Minds Biosciences Inc (DRUG)

Bright Minds Biosciences Inc (DRUG)
34.01 x 1 38.20 x 1
Post-market by (Cboe BZX)
36.50 +0.33 (+0.91%) 03/28/25 [NASDAQ]
34.01 x 1 38.20 x 1
Post-market 36.50 unch (unch) 16:00 ET
Quote Overview for Fri, Mar 28th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
35.59
Day High
36.75
Open 35.67
Previous Close 36.17 36.17
Volume 26,040 26,040
Avg Vol 39,022 39,022
Stochastic %K 69.98% 69.98%
Weighted Alpha -27.36 -27.36
5-Day Change +1.35 (+3.84%) +1.35 (+3.84%)
52-Week Range 0.93 - 79.02 0.93 - 79.02
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 254,781
  • Shares Outstanding, K 7,044
  • Annual Sales, $ 0 K
  • Annual Income, $ -2,060 K
  • EBIT $ -2 M
  • EBITDA $ -2 M
  • 60-Month Beta -6.45
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.82

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.38
  • Number of Estimates 2
  • High Estimate -0.20
  • Low Estimate -0.56
  • Prior Year -0.10
  • Growth Rate Est. (year over year) -280.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
31.05 +17.55%
on 03/04/25
Period Open: 37.24
38.00 -3.95%
on 03/24/25
-0.74 (-1.99%)
since 02/28/25
3-Month
28.21 +29.39%
on 01/28/25
Period Open: 39.88
47.50 -23.16%
on 02/13/25
-3.38 (-8.48%)
since 12/27/24
52-Week
0.93 +3,824.73%
on 04/30/24
Period Open: 1.20
79.02 -53.81%
on 10/18/24
+35.30 (+2,941.92%)
since 03/28/24

Most Recent Stories

More News
Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research

DRUG : 36.50 (+0.91%)
DRUG.CN : 52.0600 (-1.21%)
Bright Minds Biosciences to Participate at Three Healthcare Conferences in March

DRUG : 36.50 (+0.91%)
DRUG.CN : 52.0600 (-1.21%)
Biotechs on the Brink: 2 Stocks With Huge Potential

BriaCell Therapeutics and Recursion Pharmaceuticals are two biotech firms that may be poised for success in 2025; risk-tolerant investors might keep an eye out.

DRUG : 36.50 (+0.91%)
BCTX : 3.97 (-1.73%)
RXRX : 5.81 (-2.68%)
Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer

DRUG : 36.50 (+0.91%)
DRUG.CN : 52.0600 (-1.21%)
Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting

DRUG : 36.50 (+0.91%)
DRUG.CN : 52.0600 (-1.21%)
Meet the Biotech Stock That Has Generated Nvidia-Like Returns in Less Than a Month

The reason for the stock's rapid ascent is a mystery.

DRUG : 36.50 (+0.91%)
NVDA : 109.67 (-1.58%)
Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement

DRUG : 36.50 (+0.91%)
DRUG.CN : 52.0600 (-1.21%)
Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data

DRUG : 36.50 (+0.91%)
DRUG.CN : 52.0600 (-1.21%)
MarketBeat Week in Review – 10/14 - 10/18

Stocks struggled for direction, but the trend before tech earnings is still bullish. Nevertheless, investors should expect volatility ahead of the election.

WHR : 89.51 (-3.75%)
DRUG : 36.50 (+0.91%)
GOOGL : 154.33 (-4.88%)
NVDA : 109.67 (-1.58%)
CRWD : 357.11 (-2.58%)
CVX : 166.09 (-0.34%)
BAC : 41.25 (-3.08%)
OXY : 48.83 (-1.37%)
TSLA : 263.55 (-3.51%)
ABT : 130.82 (-0.40%)
XOM : 117.73 (-0.14%)
HOOD : 41.92 (-4.71%)
Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement

DRUG : 36.50 (+0.91%)
DRUG.CN : 52.0600 (-1.21%)
Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models

DRUG : 36.50 (+0.91%)
DRUG.CN : 52.0600 (-1.21%)
Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA™ Technology

DRUG : 36.50 (+0.91%)
AIFF : 4.11 (+0.49%)
DRUG.CN : 52.0600 (-1.21%)
Bright Minds Biosciences Stock Surges Almost 1,500%

Bright Minds Biosciences (NASDAQ: DRUG) soared 1,445% in a single day, trading over 100 million shares without any news.

DRUG : 36.50 (+0.91%)
Bright Minds is Unaware of Any Material Changes

Vancouver, British Columbia--(Newsfile Corp. - October 15, 2024) - At the request of CIRO, Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ("Bright Minds" or the "Company") wishes to confirm that...

DRUG : 36.50 (+0.91%)
DRUG.CN : 52.0600 (-1.21%)
Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events

DRUG : 36.50 (+0.91%)
DRUG.CN : 52.0600 (-1.21%)
Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy

/CNW/ - Bright Minds Biosciences Inc. (NASDAQ: DRUG), a biotechnology company focused on developing novel therapies for neurological and neuropsychiatric...

DRUG : 36.50 (+0.91%)
Bright Minds Announces Non-Brokered Private Placement Fully Subscribed by Management

/CNW/ - Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ("Bright Minds" or the "Company"), a leading biotechnology company specializing in the...

DRUG.CN : 52.0600 (-1.21%)
DRUG : 36.50 (+0.91%)
Biotech Market Update: Global Pharmaceuticals Market Expected to Reach $1.5 Trillion by Year’s End

EQNX::TICKER_START (NYSE:PTN),(NASDAQ:CRDF),(NASDAQ:BDRX),(NASDAQ:DRUG),(NYSE:LLY) EQNX::TICKER_END

CRDF : 3.29 (-4.36%)
BDRX : 1.2300 (-4.65%)
DRUG : 36.50 (+0.91%)
LLY : 822.51 (+0.10%)
PTN : 0.6621 (-5.41%)
Biotech Market Update: Global Pharmaceuticals Market Expected to Reach $1.5 Trillion by Year's End

/PRNewswire/ -- About 9.4% of the world population is aged 65 or above. Older people typically consume more medicines than the people in other age group...

PTN : 0.6621 (-5.41%)
CRDF : 3.29 (-4.36%)
BDRX : 1.2300 (-4.65%)
DRUG : 36.50 (+0.91%)
LLY : 822.51 (+0.10%)
New Study Reveals Psychedelic Drugs Can Be Almost as Life-Changing as Near-Death Experiences

A new study undertaken by experts at John Hopkins University School of Medicine has revealed that taking psychedelics can have the same transformational effects as a near-death experience (NDE). The study...

NUMI : 24.74 (+0.41%)
HCA : 342.16 (-0.05%)
DRUG : 36.50 (+0.91%)
DRUG.CN : 52.0600 (-1.21%)
LFST : 6.70 (-1.03%)
NUMIF : 0.0178 (-7.29%)
NUMI.TO : 0.0500 (+42.86%)
ACHC : 30.12 (unch)
New Study Reveals Psychedelic Drugs Can Be Almost as Life-Changing as Near-Death Experiences

/PRNewswire/ -- A new study undertaken by experts at John Hopkins University School of Medicine has revealed that taking psychedelics can have the same...

NUMI.TO : 0.0500 (+42.86%)
DRUG.CN : 52.0600 (-1.21%)
NUMIF : 0.0178 (-7.29%)
HCA : 342.16 (-0.05%)
DRUG : 36.50 (+0.91%)
LFST : 6.70 (-1.03%)
ACHC : 30.12 (unch)
New Study Reveals Psychedelic Drugs Can Be Almost as Life-Changing as Near-Death Experiences

FN Media Group Presents Microsmallcap.com Market Commentary   New York, NY – October 5, 2022 –  A new study undertaken by experts at John Hopkins University School of Medicine has revealed that taking...

HCA : 342.16 (-0.05%)
DRUG : 36.50 (+0.91%)
DRUG.CN : 52.0600 (-1.21%)
LFST : 6.70 (-1.03%)
ACHC : 30.12 (unch)
NUMI.TO : 0.0500 (+42.86%)
NUMIF : 0.0178 (-7.29%)
Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development Organization

VANCOUVER, British Columbia, June 27, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE:...

OTC.VN : 0.275 (-1.79%)
DRUG : 36.50 (+0.91%)
DRUG.CN : 52.0600 (-1.21%)
Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development Organization

VANCOUVER, British Columbia, June 27, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE:...

OTC.VN : 0.275 (-1.79%)
DRUG : 36.50 (+0.91%)
DRUG.CN : 52.0600 (-1.21%)
Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome

-- Review of Phase I ready BMB-101 and upcoming milestones -- -- Webcast to be held on May 19, 2022, 4:00pm ET -- VANCOUVER, British Columbia, May ...

OTC.VN : 0.275 (-1.79%)
DRUG : 36.50 (+0.91%)
DRUG.CN : 52.0600 (-1.21%)
Bright Minds Biosciences Establishes Scientific Advisory Board, Comprising Five Preeminent Physicians and Scientists Across Mental Health Specialties

-- Herbert Y. Meltzer, MD; Karl Deisseroth, MD, PhD; Robert C. Malenka, MD, PhD; Michael P. Bogenschutz, MD; and Peter Hendricks, PhD, bring decades of...

DRUG.CN : 52.0600 (-1.21%)
DRUG : 36.50 (+0.91%)
OTC.VN : 0.275 (-1.79%)
Bright Minds Biosciences to Host Symposium on Therapeutic Developments within Dravet Syndrome and Featuring a Panel with Key Opinion Leaders

-- Review of Phase I ready BMB-101 and upcoming milestones -- -- Conference call to be held on May 19, 2022, 10:00am ET -- VANCOUVER, British...

OTC.VN : 0.275 (-1.79%)
DRUG : 36.50 (+0.91%)
DRUG.CN : 52.0600 (-1.21%)
Bright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial

VANCOUVER, British Columbia, March 14, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE:...

OTC.VN : 0.275 (-1.79%)
DRUG : 36.50 (+0.91%)
DRUG.CN : 52.0600 (-1.21%)
Bright Minds Biosciences to Present at the Oppenheimer 32nd Annual Healthcare Conference

VANCOUVER, British Columbia, March 08, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE:...

OTC.VN : 0.275 (-1.79%)
DRUG : 36.50 (+0.91%)
DRUG.CN : 52.0600 (-1.21%)
Bright Minds Biosciences to Present at the H.C. Wainwright Bioconnect Conference

VANCOUVER, British Columbia, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE:...

OTC.VN : 0.275 (-1.79%)
DRUG : 36.50 (+0.91%)
DRUG.CN : 52.0600 (-1.21%)

Business Summary

Bright Minds Biosciences is a biotechnology company. It focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain. Bright Minds Biosciences is based in VANCOUVER, British Columbia.

See More

Key Turning Points

3rd Resistance Point 38.14
2nd Resistance Point 37.44
1st Resistance Point 36.97
Last Price 36.50
1st Support Level 35.81
2nd Support Level 35.11
3rd Support Level 34.64

See More

52-Week High 79.02
Fibonacci 61.8% 49.19
Fibonacci 50% 39.97
Last Price 36.50
Fibonacci 38.2% 30.76
52-Week Low 0.93

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies